Industry news

Morphosys AG acquires Lanthio Pharma B.V. and its novel drug LP 2

Read time: 1 mins

Last updated:8th May 2015

Published:8th May 2015

Source: Pharmawand

MorphoSys AG announced that it has acquired all outstanding shares of the Dutch biopharmaceutical company Lanthio Pharma B.V. The transaction brings Lanthio Pharma's lead compound LP2, a novel lanthipeptide in development for diabetic nephropathy and fibrotic diseases to MorphoSys's growing proprietary portfolio. LP2, which will be re-named MOR 107, has demonstrated potent angiotensin II type 2 (AT2) receptor-dependent activity in vivo, and is planned to enter clinical trials in 2016. LP2 is the most advanced of four lanthipeptides in Lanthio Pharma's portfolio. In this context, MorphoSys reconfirmed its updated financial guidance issued on March 26, 2015.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Industry news

Ono Pharma to acquire Deciphera Pharma

Deciphera Pharmaceuticals, Inc. a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, announced that it has entered into a definitive merger agreement with ONO Pharmaceutical Co., Ltd. (ONO), under which ONO will acquire all outstanding shares of Deciphera common stock for $25.60 per share in cash through a tender offer followed by a merger of Deciphera with a wholly-owned subsidiary of ONO (the “Acquisition”), for a total equity value of $2.4 billion

1 mins

Industry news

Xoma Corporation announces completion of acquisition of shares of Kinnate Biopharma Inc.

XOMA Corporation, a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health

1 min

Industry news

Regeneron Pharma and Mammoth Biosciences collaborate on CRISPR based gene editing therapies.

Regeneron Pharmaceuticals, Inc. and Mammoth Biosciences, Inc., announced a collaboration to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types

1 min

See all news